Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2013

01-11-2013 | Poster presentation

PB.53: Are ethnic minorities more likely to develop triple-negative breast cancer? A systematic review

Authors: R Limbada, A Slater, AK Jain

Published in: Breast Cancer Research | Special Issue 1/2013

Login to get access

Excerpt

Triple-negative breast cancer (TNBC) accounts for 10 to 15% of diagnosed breast cancers worldwide. TNBC is negative for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expression, and is associated with a poor prognosis. Our study aims to systematically review the possible link between various minority ethnic groups and development of TNBC. …
Metadata
Title
PB.53: Are ethnic minorities more likely to develop triple-negative breast cancer? A systematic review
Authors
R Limbada
A Slater
AK Jain
Publication date
01-11-2013
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2013
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3553

Other articles of this Special Issue 1/2013

Breast Cancer Research 1/2013 Go to the issue

Poster presentation

PB.41: Audit of screening-detected breast cancers with discordant interpretations on double-read screening mammography

Poster presentation

PB.30: What is your biopsy threshold in symptomatic clinic and what should it be? B2:B5 biopsy ratio: 18 months in our centre

Poster presentation

PB.47: Mammography in symptomatic women aged 35 to 39 years

Poster presentation

PB.38: In the context of overdiagnosis, does size matter?

Poster presentation

PB.03: Evaluating the role of breast MRI at mid-cycle chemotherapy

Poster presentation

PB.29: Ultrasound-guided vacuum-assisted percutaneous excision of breast papillomas: results of long-term follow-up
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits